Peptilogics, a Pittsburgh, PA- and San Jose, CA-based pre-clinical stage company utilizing an innovative peptide platform to treat multidrug-resistant bacterial infections, closed a $5.5m Series A financing.
Backers included Peter Thiel, Stefan Roever, BlueTree Ventures and others.
The company intends to use the funds to expand its eCAP platform, particularly the continued development of its first clinical candidate in preparation for an IND submission next year.
Founded by Jonathan Steckbeck, who serves as President and Chief Scientific Officer, and led by newly appointed CEO Sanjay Kakkar, Peptilogics is an early-stage biotechnology company developing a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections.
FinSMEs
29/09/2017